| Panagopoulos, Periklis |
| Terminated | 3 | 205 | Europe, RoW | Plitidepsin, Dexamethasone, Remdesivir, Favipiravir | PharmaMar | COVID-19 Infection | 03/23 | 03/23 | | |
| Recruiting | 3 | 330 | Europe | Clarithromycin 500mg, A β-lactam/β-lactamase inhibitor or a 3rd generation cephalosporin or a fluoroquinolone, Tablets | Hellenic Institute for the Study of Sepsis | Community-acquired Pneumonia | 11/25 | 01/26 | | |
MODIFY, NCT05909683: Assessing the Procalcitonin-guidance and Molecular-guided Diagnosis for Therapy of Severe Infections (the Trial) |
|
|
| Recruiting | 3 | 190 | Europe | Change of antimicrobials based on BCID2 and Reveal Rapid AST tests. Stop of antimicrobials based on PCT results., Standard of Care | Hellenic Institute for the Study of Sepsis | Sepsis | 07/25 | 07/25 | | |
| Recruiting | 2/3 | 182 | Europe | Placebo, Anakinra 149 MG/ML Prefilled Syringe [Kineret] | Hellenic Institute for the Study of Sepsis | Post-Acute COVID-19 Syndrome, Post-Acute COVID-19, Long COVID | 08/25 | 08/25 | | |
NCT05279352: Safety and Pharmacokinetics of FBR-002 for the Treatment of Patients Hospitalized With COVID-19 in Need of Supplemental Oxygen and at Risk of Severe Outcome |
|
|
| Recruiting | 2a | 30 | Europe | FBR-002, Placebo | Fab'entech | COVID-19 | 06/22 | 07/22 | | |
| Completed | 2 | 44 | Europe | Bezlotoxumab, Standard-of-care treatment according to local guidelines or to the decision of the attending physicians., Normal saline 0.9% or 5% dextrose water, Standard-of-care treatment according to local guidelines or to the decision of the attending physicians | Hellenic Institute for the Study of Sepsis | Clostridioides Difficile Infection, Stool Microbiome, Organ Dysfunction Syndrome, Clostridioides Difficile Infection Recurrence, Mortality | 06/23 | 06/23 | | |
